0001764013-23-000006.txt : 20230113 0001764013-23-000006.hdr.sgml : 20230113 20230113081329 ACCESSION NUMBER: 0001764013-23-000006 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20230111 FILED AS OF DATE: 20230113 DATE AS OF CHANGE: 20230113 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Macias William L. CENTRAL INDEX KEY: 0001864280 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38906 FILM NUMBER: 23527317 MAIL ADDRESS: STREET 1: C/O IMMUNOVANT, INC. STREET 2: 320 WEST 37TH STREET, 6TH FLOOR CITY: NEW YORK STATE: NY ZIP: 10018 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Immunovant, Inc. CENTRAL INDEX KEY: 0001764013 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 832771572 STATE OF INCORPORATION: DE FISCAL YEAR END: 0331 BUSINESS ADDRESS: STREET 1: 320 WEST 37TH STREET CITY: NEW YORK STATE: NY ZIP: 10018 BUSINESS PHONE: 917-580-3099 MAIL ADDRESS: STREET 1: 320 WEST 37TH STREET CITY: NEW YORK STATE: NY ZIP: 10018 FORMER COMPANY: FORMER CONFORMED NAME: Health Sciences Acquisitions Corp DATE OF NAME CHANGE: 20190108 4 1 wf-form4_167361559332752.xml FORM 4 X0306 4 2023-01-11 0 0001764013 Immunovant, Inc. IMVT 0001864280 Macias William L. C/O IMMUNOVANT, INC. 320 W 37TH STREET, 6TH FLOOR NEW YORK NY 10018 0 1 0 0 Chief Medical Officer Common Stock 2023-01-11 4 S 0 120 15.11 D 307981 D Common Stock 2023-01-11 4 S 0 44448 16.75 D 263533 D On November 5, 2021, the holder was granted 112,108 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on November 9, 2021. These RSUs vested in their entirety on January 1, 2023. Amounts reported herein represent shares sold by the holder solely to satisfy the holder's tax withholding obligation due in connection with the vesting and settlement of these RSUs and do not represent a discretionary sale by the holder. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.06 - $15.15 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.30 - $16.80 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. /s/ Eva Renee Barnett, attorney-in-fact for William L. Macias 2023-01-13